Xiaoxiao Yang

Prof. Xiaoxiao Yang


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ZXZhouling Xie
Zhouling Xie
XYXiaoxiao Yang
Xiaoxiao Yang
YDYajun Duan
Yajun Duan
JHJihong Han
Jihong Han
CLChenzhong Liao
Chenzhong Liao

1 March 2019 in Pharmacological Research
Verified
Journal Article
Closed access
Jihong HanJihong Han
Jihong Han
HTHao Tan
Hao Tan
YDYajun Duan
Yajun Duan
YCyuanli chen
yuanli chen
YZYan Zhu
Yan Zhu
XYXiaoxiao Yang
Xiaoxiao Yang

2 March 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ZXZhouling Xie
Zhouling Xie
SHShuzeng Hou
Shuzeng Hou
XYXiaoxiao Yang
Xiaoxiao Yang
YDYajun Duan
Yajun Duan
JHJihong Han
Jihong Han
CLChenzhong Liao
Chenzhong Liao

1 December 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ZZZhen Zhang
Zhen Zhang
PCPeichang Cao
Peichang Cao
MFMengyuan Fang
Mengyuan Fang
TZTingfeng Zou
Tingfeng Zou
JHJihong Han
Jihong Han
QLQing-Shan Li
Qing-Shan Li

24 May 2023 in Acta Pharmacologica Sinica
Verified
Journal Article
Open access
PDF file
TZTing-Feng Zou
Ting-Feng Zou
ZLZhi-Gang Liu
Zhi-Gang Liu
PCPei-Chang Cao
Pei-Chang Cao
SZShi-Hong Zheng
Shi-Hong Zheng
WGWen-Tong Guo
Wen-Tong Guo
XYXiaoxiao Yang
Xiaoxiao Yang
Diabetes-related vascular complications include diabetic cardiovascular diseases (CVD), diabetic nephropathy (DN) and diabetic retinopathy, etc. DN can promote the process of end-stage renal disease. On the other hand, atherosclerosis accelerates kidney damage. It is really an urge to explore the mechanisms of diabetes-exacerbated atherosclerosis as well as new agents for treatment of diabetes-exacerbated atherosclerosis and the complications. In this study we investigated the therapeutic effects of fisetin, a natural flavonoid from fruits and vegetables, on kidney injury caused by streptozotocin (STZ)-induced diabetic atherosclerosis in low density lipoprotein receptor deficient (LDLR−/−) mice. Diabetes was induced in LDLR−/− mice by injecting STZ, and the mice were fed high-fat diet (HFD) containing fisetin for 12 weeks. We found that fisetin treatment effectively attenuated diabetes-exacerbated atherosclerosis. Furthermore, we showed that fisetin treatment significantly ameliorated atherosclerosis-enhanced diabetic kidney injury, evidenced by regulating uric acid, urea and creatinine levels in urine and serum, and ameliorating morphological damages and fibrosis in the kidney. In addition, we found that the improvement of glomerular function by fisetin was mediated by reducing the production of reactive oxygen species (ROS), advanced glycosylation end products (AGEs) and inflammatory cytokines. Furthermore, fisetin treatment reduced accumulation of extracellular matrix (ECM) in the kidney by inhibiting the expression of vascular endothelial growth factor A (VEGFA), fibronectin and collagens, while enhancing matrix metalloproteinases 2 (MMP2) and MMP9, which was mainly mediated by inactivating transforming growth factor β (TGFβ)/SMAD family member 2/3 (Smad2/3) pathways. In both in vivo and in vitro experiments, we demonstrated that the therapeutic effects of fisetin on kidney fibrosis resulted from inhibiting CD36 expression. In conclusion, our results suggest that fisetin is a promising natural agent for the treatment of renal injury caused by diabetes and atherosclerosis. We reveal that fisetin is an inhibitor of CD36 for reducing the progression of kidney fibrosis, and fisetin-regulated CD36 may be a therapeutic target for the treatment of renal fibrosis.

10 August 2022 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
PDF file
DYDai-Gang Yang
Dai-Gang Yang
YGYong-Yao Gao
Yong-Yao Gao
ZYZe-Qun Yin
Ze-Qun Yin
XWXue-Rui Wang
Xue-Rui Wang
XMXian-She Meng
Xian-She Meng
XYXiaoxiao Yang
Xiaoxiao Yang